EVMN Evommune, Inc.
Price Chart
Executive Summary
Three top executives at Evommune (CEO, CFO, CLO) sold a combined $1.12M in open-market sales over a 5-day window, representing ~0.16% of the $714M market cap. The cluster is modest in size relative to market cap, but the involvement of the entire C-suite in coordinated selling is notable. The stock has been under severe pressure (avg -14% T+20 on prior reports), and the cross-filing actuarial verdicts strongly amplify the signal of insider trades combined with earnings, offering, and press contexts.
Key Financial Metrics
Actionable Insight
The coordinated C-suite selling at a company with a 94% analyst buy rating and a stock that has been persistently declining is a red flag. The cross-filing amplifiers suggest this cluster is more informative than standalone. Traders should watch for upcoming earnings or material news that could explain the insider exits, and consider reducing long exposure or adding protective puts.
Key Facts
- CEO Luis Pena sold $382K in open-market shares on June 1, 2026.
- CFO Kyle Carver sold $415K in open-market shares on May 28, 2026.
- CLO Gregory Moss sold $325K in open-market shares on May 28, 2026.
- Total insider sales of $1.12M represent ~0.16% of the $714M market cap.
- All three sales were open-market (code S), not tax-withholding or derivative exercises.
- The stock has declined an average of 14.11% at T+20 across the last 6 reports on this ticker.
Financial Impact
Total insider sales of $1.12M, or ~0.16% of market cap — modest in absolute size but significant given the C-suite coordination.
Risk Factors
- Insiders may be reacting to upcoming negative news (e.g., clinical trial failure, regulatory setback, or earnings miss).
- The stock has shown persistent negative drift (avg -14% T+20) — selling pressure may continue regardless of fundamentals.
- Despite 94% analyst bullishness, insider behavior is contradicting the consensus, creating a credibility gap.
Market Snapshot
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-EVMN-1780531355841 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
1d ago
|
Insider Cluster
| — | awaiting T+20 | — | — |
|
Jun 2, 2026
2d ago
|
144
| — | awaiting T+20 | — | — |
|
Jun 2, 2026
3d ago
|
Insider Cluster
| — | awaiting T+20 | — | — |
|
May 28, 2026
7d ago
|
144
| $23.27 awaiting T+20 | awaiting T+20 | — | $19.83 (+14.79%) |
|
Apr 27, 2026
5w ago
|
EFFECT
| $25.00 $23.35 | ▼ −6.60% | ▼ −11.56% | $19.83 (−20.70%) |
|
Apr 21, 2026
6w ago
|
DEFA14A
| $27.12 $21.12 | ▼ −22.12% | ▼ −25.29% | $19.83 (−26.90%) |
|
Apr 17, 2026
6w ago
|
S-1
| $27.97 $21.89 | ▼ −21.74% | ▼ −25.94% | $19.83 (−29.12%) |
|
Apr 13, 2026
7w ago
|
8-K
| $26.63 $23.21 | ▼ −12.84% | ▼ −19.14% | $19.83 (−25.55%) |
|
Mar 5, 2026
13w ago
|
8-K
| $26.50 $24.58 | ▼ −7.25% | ▼ −5.20% | $19.83 (−25.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access